Cassava Sciences

Historical price data

Cassava Sciences is a mission-driven biotech focused on developing transformative treatments for Alzheimer's disease, a market with profound unmet need. Its core strategy is built on a unique scientific platform targeting altered filamin A (FLNA) protein to stabilize disease pathology. The company's primary achievement is the advancement of its lead drug, simufilam, into two large, global Phase 3 efficacy and safety trials. Cassava's strategy hinges on successfully demonstrating simufilam's clinical benefit to secure regulatory approval and address a multi-billion dollar market.

A drug discovery platform focused on identifying small molecules that bind to and restore the normal shape of altered filamin A (FLNA) protein, a hypothesized central driver of Alzheimer's pathology involving amyloid, tau, and neuroinflammation.

Competes directly with approved anti-amyloid antibodies (Leqembi, pending donanemab) which set a high efficacy/safety bar. Also faces competition from other late-stage programs targeting tau, neuroinflammation, and synaptic function, many with greater resources and established clinical data.